Treatment | LLC/CMV | LLC/cMOAT-1 | ||
---|---|---|---|---|
IC50 | DMF2-a | IC50 | DMF | |
μM | μM | |||
VCR | 0.029 ± 0.002 (1)2-b | 0.234 ± 0.0182 (8.02) | ||
+ CsA (10 μM) | 0.024 ± 0.003 (0.83) | 1.21 | 0.045 ± 0.004 (1.55) | 5.202-c |
+ PAK-104P (5 μM) | 0.020 ± 0.002 (0.69) | 1.452-c | 0.051 ± 0.007 (1.75) | 4.592-c |
+ MK571 (5 μM) | 0.028 ± 0.003 (0.97) | 1.04 | 0.083 ± 0.003 (2.86) | 2.822-c |
+ PSC833 (10 μM) | 0.022 ± 0.002 (0.76) | 1.322-c | 0.098 ± 0.014 (3.38) | 2.392-c |
+ BSO (10 μM) | 0.027 ± 0.004 (0.93) | 1.07 | 0.122 ± 0.015 (4.20) | 1.92-c |
SN-38 | 0.065 ± 0.007 (1) | 0.408 ± 0.041 (6.28) | ||
+ CsA (10 μM) | 0.060 ± 0.005 (0.92) | 1.08 | 0.088 ± 0.008 (1.35) | 4.62-c |
+ PAK-104P (5 μM) | 0.058 ± 0.006 (0.90) | 1.11 | 0.096 ± 0.012 (1.48) | 4.252-c |
+ MK571 (5 μM) | 0.066 ± 0.007 (1.02) | 0.98 | 0.153 ± 0.012 (2.35) | 2.672-c |
+ PSC833 (10 μM) | 0.061 ± 0.007 (0.94) | 1.07 | 0.193 ± 0.024 (2.97) | 2.12-c |
+ BSO (10 μM) | 0.051 ± 0.008 (0.88) | 1.14 | 0.158 ± 0.019 (2.43) | 2.582-c |
Cisplatin | 2.576 ± 0.354 (1) | 7.820 ± 0.844 (3.04) | ||
+ CsA (10 μM) | 2.464 ± 0.211 (0.96) | 1.05 | 3.060 ± 0.421 (1.19) | 2.562-c |
+ PAK-104P (5 μM) | 2.412 ± 0.202 (0.94) | 1.07 | 3.211 ± 0.421 (1.25) | 2.442-c |
+ MK571 (5 μM) | 2.520 ± 0.311 (0.98) | 1.02 | 3.989 ± 0.431 (1.55) | 1.962-c |
+ PSC833 (10 μM) | 2.487 ± 0.233 (0.99) | 1.01 | 4.908 ± 0.601 (1.91) | 1.592-c |
+ BSO (10 μM) | 2.101 ± 0.312 (0.82) | 1.23 | 3.616 ± 0.521 (1.40) | 2.162-c |
To examine the effects of CsA, PSC833, MK571, PAK-104P or BSO on drug sensitivity, cells were preincubated with or without CsA, PSC833, MK571, or PAK-104P for 1 h or BSO for 24 h and then incubated with various concentrations of drugs. Data represent means of triplicate determinations (± S.E.) from at least three separate experiments.
↵2-a DMF, dose-modifying factor (IC50 value of drug in cells was divided by IC50 value of drug combined with reversing agents).
↵2-b Relative resistance (IC50 of drug for LLC/CMV with the reversing agents or LLC/cMOAT-1 with and without the reversing agents was divided by IC50 for LLC/CMV of drug without the reversing agents).
↵2-c Values obtained for drug combined with the reversing agents, are significantly different from those obtained for drug alone (P < .05).